



Sheet 1 of 2

Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO.	2543-1-034
	SERIAL NO.	10/736,461
	APPLICANT	Jonathan A. Terrett
	FILING DATE	December 15, 2003
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	GROUP	Unknown 1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLAS S	SUB- CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLAS S	SUB- CLASS	TRANSLATION YES NO
anh	BA	JP11146790 ABSTRACT	6/2/99	JAPAN			
↓	BB	WO 01/98318	12/27/01	PCT			
	BC	WO 00/55351	9/21/00	PCT			

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

anh	CA	Baselga, J., et al., Recombinant Humanized Anti-HER2 Antibody(Herceptin™)Enhances the Antitumor Activity of Paclitaxel and Doxorubicin against HER2/neu Overexpressing Human Breast Cancer Xenografts ¹ , 1998, Cancer Res. 58: 2825-2831
↓	CB	Catimel, B., et al.,Purification and Characterization of a Novel Restricted Antigen Expressed by Normal and Transformed Human Colonic Epithelium, 1996, J. Biol. Chem. 271:25664-25670
	CC	Davis, ID,et al,An overview of Cancer immunotherapy 2000, Immunol. Cell Biol. 78: 179-196
	CD	Dillman, R.O.,Perceptions of Herceptin®:A Monoclonal Antibody for the Treatment of Breast Cancer,1999, Cancer Biother. Radiopham. 14: 5-10
	CE	Green,MC,etal,Monoclonal antibody therapy for solid tumors,2000,Cancer Treat Rev 26:269-86
↓	CF	Hastbacka J,et al,The Diastrophic Dysplasia Gene Encodes a Novel Sulfate Transporter Positional Cloning by Fine-Structure Linkage Disequilibrium Mapping,1994,Cell 78(6):1073-87
	CG	Hastbacka J., et al.,Atelosteogenesis Type II Is Caused by Mutations in the Diastrophic Displasia Sulfate-Transporter Gene(DTDST):Evidence for a Phenotypic Series Involving Three Chondrodysplasias, 1996, Am. J. Hum. Genet.58(2):255-62
EXAMINER: <i>anh</i>		DATE CONSIDERED: 5 January 2007
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		



Form PTO:1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office	ATTORNEY, DOCKET NO.	2543-1-034
	SERIAL NO.	10/736,461
LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary)	APPLICANT	Jonathan A. Terrett
	FILING DATE	December 15, 2003
	GROUP	Unknown 1643

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

amh	CH	Hubert, R.S. et al., STEAP: A prostate-specific cell-surface antigen highly expressed in human prostate tumors 1999, Pro. Natl Acad. Sci. USA 96: 14523-14528
	CI	Knuth, A. et al., Cancer immunotherapy in clinical oncology 2000, Cancer Chemother. Pharmacol. 46, S46-51
	CJ	Lucas S., et al., MAGE-5B, MAGE-B6, MAGE-C2, and MAGE-C3: Four New Members Of The MAGE Family With Tumor-Specific Expression 2000, Int.J. Cancer 87:55-60
	CK	Miller, K.D., et al., Toward checkmate: biology and breast cancer therapy for the new millennium 1999, Invest. New Drugs 17: 417-427
	CL	Safran, D.C., et al., Target antigens for prostate cancer immunotherapy 1999, Cancer Metastasis Rev. 18: 437-449
	CM	Shiku, H., et al., Development of a cancer vaccine: peptides, proteins, and DNA 2000, Cancer Chemother. Pharmacol. 46:S77-82
✓	CN	Stebbing, J., et al., Herceptin (trastuzumab) in advanced breast cancer 2000, Cancer Treat. Rev. 26:287-290
✓	CO	Superti-Furga A., et al., Achondrogenesis type IB is caused by mutations in the diastrophic dysplasia sulphate transporter gene, 1996, Nature Genet. 12(1):100-2
EXAMINER: amh		DATE CONSIDERED: 5/January 2007
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant		